Time filter

Source Type

Qin X.,First Peoples Hospital of Kashgar Prefecture | Zhang J.,First Peoples Hospital of Kashgar Prefecture | Li Y.,Guangdong Pharmaceutical University | Xirenbaike T.,First Peoples Hospital of Kashgar Prefecture | Yasen X.,First Peoples Hospital of Kashgar Prefecture
Chinese Journal of Clinical Oncology | Year: 2013

Objective: To investigate the incidence and distribution of malignant tumor in Uygur People and provide a theoretical basis for epidemiological surveys. Methods: A retrospective study was conducted from November 2007 to October 2012 on inpatients with malignant tumors at The First People' s Hospital of Kashgar Prefecture. The top 10 kinds of malignant tumor were found in Uygur People and Han People. Results: A total of 7578 patients were registered, including 6840 (about 90.26%) Uygur People, 628 (nearly 8.29%) Han People, and 110 (about 1.45%) from other minority groups. The top 10 kinds of malignant tumor for Uygur People were gastric cancer, esophageal cancer, leukemia, cervical cancer, malignant lymphoma, primary hepatic carcinoma, breast cancer, head and neck cancer, lung cancer, and colorectal cancers. Meanwhile, the order for Han People were lung cancer, colorectal cancer, breast, gastric, primary hepatic, head and neck, leukemia, cervical, esophageal cancer, and pancreatic cancer. Conclusion: A different epidemic character of malignant tumor existed between Uygur People and Han People in Kashga, Xinjiang.


Qin X.,Guangdong Pharmaceutical University | Hao S.,First Peoples Hospital of Kashgar Prefecture | Xirenbaike T.,First Peoples Hospital of Kashgar Prefecture | Li Y.,Guangdong Pharmaceutical University | Abudula G.,First Peoples Hospital of Kashgar Prefecture
Chinese Journal of Clinical Oncology | Year: 2014

Objective: This study aimed to compare the differences in molecular subtypes between Uygur and Han patients with breast cancer. This study was also conducted to provide clinical recommendations. Methods: The new typing standard of St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 was used to classify the molecular subtypes of 369 breast cancer cases from the First People's Hospital of Kashgar Prefecture, Xinjiang Uygur Autonomous Region, China. Four immunohistochemical markers (ER, PR, HER-2, and Ki-67) were used to divide the patients into four intrinsic subtypes: Luminal A; Luminal B (divided into HER-2 negative subtype and HER-2 positive subtype); HER-2 enriched; and triple negative breast cancer (TNBC) subtype. Statistical analysis was then conducted to evaluate the differences in molecular subtype characteristics of Uygur and Han patients with breast cancer. Results: The proportion of Luminal A, Luminal B with HER-2 negative subtype, Luminal B with HER-2 positive subtype, HER-2 enriched, and TNBC subtype were 12.67% (36/284), 34.51% (98/284), 20.07% (57/284), 14.79% (42/284), and 17.96% (51/284) for 284 Uygur patients with breast cancer; the corresponding proportions were 16.47% (14/85), 37.65% (32/85), 10.59% (9/85), 10.59% (9/85), and 24.71% (21/85) for 85 Han patients with breast cancer, respectively. The HER-2 positive rates of Uygur and Han patients with breast cancer were 34.86% (99/284) and 21.18% (18/85), respectively. The proportions of Luminal B with HER-2 positive subtype and HER-2 positive rate were significantly higher in Uygur patients than in Han patients (P=0.045 and P=0.030, respectively). Conclusion: A larger proportion of Luminal B with HER-2 positive subtype and a higher HER-2 positive rate were observed in Uygur patients with breast cancer than in Han patients with the same disease. HER-2-targeted therapy could be more effective for Uygur patients with breast cancer than for Han patients.

Loading First Peoples Hospital of Kashgar Prefecture collaborators
Loading First Peoples Hospital of Kashgar Prefecture collaborators